Tirzepatide cost of care: over-55 data

A matched cohort analysis published on 24 August 2026 in Diabetes, Obesity and Metabolism found that adults aged over 55 with obesity or overweight but without diabetes who used tirzepatide spent $145 to $319 less per month on healthcare than matched controls in months six through eighteen of follow-up^[1]. The finding is notable because it covers a group large drug cost-effectiveness models tend to underrepresent: older adults with excess weight but without a diabetes diagnosis.

What the study measured

Researchers drew on US real-world data from November 2022 through September 2025, covering 15,843 matched pairs. Each tirzepatide user was matched to a non-user on age, sex, baseline body mass index, and comorbidity profile. The primary outcome was total monthly healthcare expenditure. Secondary outcomes tracked emergency department visits and inpatient hospitalisation rates^[1].

The study used statistical methods that account for participant dropout and varying follow-up durations, which is a sensible approach for a real-world dataset where treatment discontinuation is common. Tirzepatide had only been commercially available since May 2022 for type-2 diabetes in the US and since November 2023 under the Zepbound brand for weight management, so the observation window is tight by outcomes-study standards.

The cost reduction numbers

Monthly cost reductions in the tirzepatide group ranged from $145 to $319 compared to controls across the observation window, representing a 12.3% to 25.4% decrease in healthcare expenditures^[1]. The reductions widened progressively among participants who maintained treatment adherence, with emergency department and inpatient hospitalisation rates in the tirzepatide group running at approximately 69% of control rates during months twelve through eighteen.

Putting those numbers in context: tirzepatide carries a US list price in the range of $1,000 per month for the Zepbound weight-management brand at the time of the study period. The $145 to $319 monthly saving in other healthcare costs does not fully offset drug acquisition cost at list price. However, for patients with employer-sponsored coverage, Medicare Part D, or commercial insurance plans that cover anti-obesity medications, the net cost picture shifts considerably.

Why older non-diabetic adults matter here

The EMA-authorised label for tirzepatide covers weight management in adults with a BMI at or above 30 kg/m², or 27 kg/m² or above with at least one weight-related comorbidity^[2]. Adults aged 55 and over with obesity sit squarely in that population. What has been less studied is how their total cost of care changes once they start treatment.

The over-55 segment is clinically relevant because excess weight in this age group is associated with elevated rates of osteoarthritis, heart failure, obstructive sleep apnea, and mobility limitation. Each of those conditions generates recurring healthcare utilisation. A drug that reduces body weight materially, and that was shown in the SURMOUNT programme to produce weight reductions averaging 15% or more on the highest dose, can plausibly reduce downstream utilisation if patients stay on treatment long enough.

What the study cannot tell us

The observation window runs to roughly 18 months. Tirzepatide's FDA prescribing information notes that the cardiovascular outcomes data are still developing^[3]; the pivotal SURMOUNT-CVOT trial has not yet read out. Whether cost offsets expand, plateau, or reverse beyond 18 months is unknown.

Matched cohort studies, even carefully constructed ones, cannot rule out all residual confounding. Patients who initiate and stay on a costly drug may differ from controls in unmeasured ways: motivation, access to primary care, and health literacy all plausibly correlate with both treatment persistence and healthcare utilisation. The authors used statistical adjustment for dropout, but the study is observational and cannot claim causation.

The US real-world data setting also limits generalisability. Drug pricing, insurance structures, and care patterns in Europe differ substantially. A matched cohort from a Danish or German payer perspective could produce a different cost picture entirely.

Where this sits in the broader evidence base

This paper adds to a growing body of real-world data on tirzepatide beyond the controlled trial setting. The SURMOUNT programme established weight-loss efficacy; studies like this one begin to map the downstream economic footprint. For anyone working through the evidence on tirzepatide for weight management, the full pharmacology and trial summary is on the tirzepatide overview page. For country-specific access and pricing, see the regulation pages for individual markets.

The headline finding, a 12-25% reduction in monthly healthcare costs in an older non-diabetic population, is worth tracking as the dataset matures. It is not yet the kind of long-horizon evidence that changes payer coverage decisions, but it points in a direction that longer follow-up studies will need to confirm or qualify.